The kit is co-developed by Singapore Agency for Science, Technology and Research (A*STAR) Experimental Drug Development Centre, Bioinformatics Institute, The Diagnostics Development (DxD) Hub and Tan Tock Seng Hospital. The kit has received Singapore Health Science Authority (HSA) approval (MDPA2020-01) and has been deployed in Singapore public and private hospital labs. qPCR testing for specific RNA in nasopharyngeal swab samples. The analytical Limit of Detection (LOD) at 25 copies/reaction. No cross-reactivity with SARS-CoV, Influenza A H1N1, Influenza A H3N2, Influenza B and MERS-CoV. No false negative has been reported to-date The kit is manufactured in Singapore
